Publications

Export 34 results:
Sort by: Author [ Title  (Asc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y [Z]   [Show ALL]
A
Waschke, O, Fehse B, Kabisch H, Zander AR, Fehse N, Renges H, Kroger N, Zabelina T, Ayuk F, Schieder H, Oyekunle AA.  2006.  Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up, Jan. Bone Marrow Transplant. 37:45-50., Number 1 AbstractWebsite

We examined retrospectively 44 patients with refractory acute leukemia (acute myeloid leukemia (AML)/acute lymphoblastic leukemia=25/19) who underwent allogeneic transplantation at our center between 11/1990 and 04/2004. The median leukemic blasts was 25% and age 28 years (range, 3-56). Twenty-one patients had untreated relapse, 13 failed reinduction, eight in partial remission and two aplastic. Conditioning was myeloablative using cyclophosphamide, busulfan, total-body irradiation and etoposide (Bu/Cy/VP, n=22; TBI/Cy/VP, n=17; others, n=5) followed by marrow or peripheral blood transplant (n=23/21) from unrelated or related donors (n=28/16). All patients had graft-versus-host disease (GVHD) prophylaxis with cyclosporin and methotrexate. One patient experienced late graft failure. Severe acute-GVHD and chronic-GVHD appeared in eight and 14 patients, respectively. Thirteen patients (30%) remain alive after a median of 25.3 months (range, 2.4-134.1); with 31 deaths, mostly from relapse (n=15) and infections (n=12). Overall survival (OS) and progression-free survival (PFS) at 5 years was 28 and 26%, respectively. OS and PFS were significantly better with blasts < or =20% and time to transplant < or =1 year while transplant-related mortality was less with the use of TBI. We conclude that patients with refractory leukemia can benefit from allogeneic BMT, especially with < or =20% marrow blast.

Salpietro, V, Dixon CL, Guo H, Bello OD, Vandrovcova J, Efthymiou S, Maroofian R, Heimer G, Burglen L, Valence S et al..  2019.  AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders, 2019. Nature Communications. 10(1) Abstract

AMPA receptors (AMPARs) are tetrameric ligand-gated channels made up of combinations of GluA1-4 subunits encoded by GRIA1-4 genes. GluA2 has an especially important role because, following post-transcriptional editing at the Q607 site, it renders heteromultimeric AMPARs Ca2+-impermeable, with a linear relationship between current and trans-membrane voltage. Here, we report heterozygous de novo GRIA2 mutations in 28 unrelated patients with intellectual disability (ID) and neurodevelopmental abnormalities including autism spectrum disorder (ASD), Rett syndrome-like features, and seizures or developmental epileptic encephalopathy (DEE). In functional expression studies, mutations lead to a decrease in agonist-evoked current mediated by mutant subunits compared to wild-type channels. When GluA2 subunits are co-expressed with GluA1, most GRIA2 mutations cause a decreased current amplitude and some also affect voltage rectification. Our results show that de-novo variants in GRIA2 can cause neurodevelopmental disorders, complementing evidence that other genetic causes of ID, ASD and DEE also disrupt glutamatergic synaptic transmission.

Atere, CT, Ge T, Zhu Z, Liu S, Huang X, Shibistova O, Guggenberger G, Wu J.  2019.  Assimilate allocation by rice and carbon stabilisation in soil: effect of water management and Phosphorus fertilisation. Plant and Soil . 445:153–167.
B
Zhu, Z, Ge T, Xiao M, Yuan H, Wang, T., Liu S, Atere CT, Wu J.  2017.  Belowground carbon allocation and dynamics under rice cultivation depends on soil organic matter content. Plant and Soil. 410:247–258.
He, K, Timmermann BN, Aladesanmi AJ, Zeng L.  1996.  A Biflavonoid from Dysoxylum lenticellare Gillespie, Phytochemistry. 42:1199-1201.
C
Atere, CT, Ge T, Zhu Z, Wei L, Zhou P, He X, Kuzyakov Y, Wu J.  2018.  Carbon allocation and fate in paddy soil depending on phosphorus fertilisation and water management: results of 13C continuous labelling of rice.. Canadian Journal of Soil Science . 98(3)::469–483.
Klingebiel, T, Fehse B, Sputtek A, Zander A, Kroger N, Zabelina T, Fehse N, Koehl U, Schieder H, Ayuk F, Renges H, Oyekunle A.  2006.  CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation. Cytotherapy. 8:375-80., Number 4 AbstractWebsite

BACKGROUND: Poor graft function without rejection may occur after stem cell transplantation (SCT). CD34(+) stem cell boost (SCB) can restore marrow function but may induce or exacerbate GvHD. We therefore investigated the feasibility and efficacy of CD34(+)-selected SCB in some patients with poor graft function. We present the results for eight patients (median age 46 years) transplanted initially for myelofibrosis, acute leukemia, myeloma and NHL. Six patients had received HLA-matched and two mismatched grafts (PB, BM; n=5, 3). After a median of 128 days post-transplant, the median leukocyte and platelet counts were, respectively, 2.05/nL and 18/nL. None had achieved platelet counts >50/nL even though donor chimerism was >95% in seven recipients. METHODS: Positive selection of CD34(+) stem cells was performed on a CliniMACS device, observing GMP and achieving a median of 98.5% purity. The patients received a median of 1.7 x 10(6)/kg CD34(+) cells and 2.5 x 10(3)/kg CD3(+) T lymphocytes. RESULTS: Hemograms at days +30, +60 and +90, respectively, showed steadily increasing median leukocyte (2.55, 3.15 and 4.20/nL) and platelet (29, 39 and 95/nL) counts. After a median follow-up of 144 days, five patients remained alive. No patient had developed acute or chronic GvHD. One patient died of leukemic relapse and two others of systemic mycosis. DISCUSSION: These preliminary results point to the possibility of safely improving graft function using CD34(+) positively selected stem cells without necessarily increasing the incidence of GvHD in patients with poor graft function post-SCT. Experience with more patients and longer follow-up should clarify the optimal role for this procedure.

Oyekunle, A, Klyuchnikov E, Ocheni S, Kroger N, Zander AR, Baccarani M, Bacher U.  2011.  Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors. Acta Haematologica. 126(1):30-39., Number 1 AbstractWebsite

Following the introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of chronic myeloid leukemia (CML) patients, the allogeneic hematopoietic stem cell transplantation (HSCT) scene in CML has changed dramatically. The number of patients receiving HSCT in first chronic phase (CP) has declined rapidly, as allogeneic HSCT in CP is now performed in these patients only in case of failure or intolerance of TKIs. Second, those CML patients who undergo allogeneic HSCT represent a selection of high-risk patients due to more advanced disease with high rates of accelerated or blast phase (being associated with an increased relapse risk), advanced age and relevant co-morbidities. Efforts at meeting these special challenges are being developed: treatment with TKIs aims to improve the pre-transplant remission status before HSCT. Dose-reduced conditioning protocols were introduced to decrease transplant-related mortality in patients with co-morbidities or older age. In the post-transplant period, TKIs may be administered for prophylaxis and for treatment of post-transplant relapse. Still, the outcome of patients in advanced CML phases remains guarded, and requires an improvement in current transplant strategies.

Jiang, CM, Duangthip D, Auychai P, Chiba M, Folayan M, Hamama H, Kamnoedboon P, Lyons K, Matangkasombut O, Mathu-Muju K, Mathur V, Mei ML, Morgan M, Poolthong S, Morankar R, Srinivasan M, Takahashi T, Yaklai S, Zhang S, Lo E.  2021.  Changes in Oral Health Policies and Guidelines During the COVID-19 Pandemic. Frontiers in Oral Health, 2021/05/21. 2 Abstract
n/a
E
Bacher, U, Zander AR, Kröger N, Ibegbulam OG, Olusina DB, Oyekunle AA, Ocheni S.  2010.  EBV-Associated Malignancies.. The Open Infect Dis Journal. 4:101-112. Abstract
n/a
Olldashi, F, Muzha I, Filipi N, Lede R, Copertari P, Traverso C, Copertari A, Vergara EA, Montenegro C, De Huidobro RR et al..  2004.  Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): Randomised placebo-controlled trial, 2004. The Lancet. 364(9442) Abstract

Background Corticosteroids have been used to treat head injuries for more than 30 years. In 1997, findings of a systematic review suggested that these drugs reduce risk of death by 1-2%. The CRASH trial—a multicentre international collaboration—aimed to confirm or refute such an effect by recruiting 20 000 patients. In May, 2004, the data monitoring committee disclosed the unmasked results to the steering committee, which stopped recruitment. Methods 10 008 adults with head injury and a Glasgow coma score (GCS) of 14 or less within 8 h of injury were randomly allocated 48 h infusion of corticosteroids (methylprednisolone) or placebo. Primary outcomes were death within 2 weeks of injury and death or disability at 6 months. Prespecified subgroup analyses were based on injury severity (GCS) at randomisation and on time from injury to randomisation. Analysis was by intention to treat. Effects on outcomes within 2 weeks of randomisation are presented in this report. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN74459797. Findings Compared with placebo, the risk of death from all causes within 2 weeks was higher in the group allocated corticosteroids (1052 [21·1%] vs 893 [17·9%] deaths; relative risk 1·18 [95% CI 1·09-1·27]; p=0·0001). The relative increase in deaths due to corticosteroids did not differ by injury severity (p=0·22) or time since injury (p=0·05). Interpretation Our results show there is no reduction in mortality with methylprednisolone in the 2 weeks after head injury. The cause of the rise in risk of death within 2 weeks is unclear.

Xiao, M, Zang H, Ge T, Chen A, Zhu Z, Zhou P, Atere CT, Wu, J., Y. S, Kuzyakov Y.  2019.  Effect of nitrogen fertilizer on rice photosynthate allocation and Carbon input in paddy soil. European Journal of Soil Science . 70(4):786–795.
Wei, X, Hu Y, Peng P, Zhu Z, Atere CT, O’Donnell AG, Wu J, Ge T.  2017.  Effect of P stoichiometry on the abundance of nitrogen-cycle genes in phosphorus-limited paddy soil. Biology and Fertility of Soils . 53:767–776..
G
Jafarinia, M, Vos T, Lim S, Naghavi M, Murray C, Onwujekwe O, Oancea B, Aravkin A, Zheng P, Cristiana A, Abbas K, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A, Abdollahi M, Abdollahpour I, Abegaz K, Abolhassani H, Aboyans V, Ghajar A.  2020.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019, 2020/10/16. 396:1204-1222. Abstract
n/a
Murray, C, Aravkin A, Zheng P, Cristiana A, Abbas K, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A, Abdollahi M, Abdollahpour I, Abegaz K, Abolhassani H, Aboyans V, Guimarães Abreu L, Abrigo M, Abualhasan A, Abu-Raddad L, Abushouk A, Adabi M.  2020.  Global burden of 87 risk factors in 204 countries and territories 1990-2019: a systematic analysis for the GBD Study 2019, 2020/10/15. 396:1223-1249. Abstract
n/a
Murray, C, Aravkin A, Zheng P, Cristiana A, Abbas K, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A, Abdollahi M, Abdollahpour I, Abegaz K, Abolhassani H, Aboyans V, Guimarães Abreu L, Abrigo M, Abualhasan A, Abu-Raddad L, Abushouk A, Adabi M, Pokhrel K.  2020.  Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019, 2020/10/17. 17:1223-1249. Abstract
n/a
H
Eilander, A, Olumakaiye M, Moretti D, Zimmermann M, Owojuyigbe T, Blonk C, Murray P, Duchateau G.  2019.  High Bioavailability from Ferric Pyrophosphate-Fortified Bouillon Cubes in Meals is Not Increased by Sodium Pyrophosphate: a Stable Iron Isotope Study in Young Nigerian Women, 2019/05/01. 149:723-729. Abstract

BackgroundIt is challenging to find an iron compound that combines good bioavailability with minimal sensory changes when added to seasonings or condiments. Ferric pyrophosphate (FePP) is currently used to fortify bouillon cubes, but its bioavailability is generally low. Previously, the addition of a stabilizer, sodium pyrophosphate (NaPP), improved iron bioavailability from a bouillon drink.
Objective
We assessed whether there is a dose-response effect of added NaPP on iron bioavailability from local meals prepared with intrinsically labeled FePP-fortified bouillon cubes in young Nigerian women using iron stable isotope techniques.
Methods
In a double-blind, randomized, cross-over trial, women (n = 24; aged 18–40 y; mean BMI 20.5 kg/m²) consumed a Nigerian breakfast and lunch for 5 d prepared with bouillon cubes containing 2.5 mg ⁵⁷Fe (as FePP) and 3 different molar ratios of NaPP: ⁵⁷Fe (0:1, 3:1, and 6:1). Iron bioavailability was assessed by measuring ⁵⁷Fe incorporation into erythrocytes 16 d after each 5 d NaPP: ⁵⁷Fe feeding period. Data were analyzed using a linear regression model of log iron absorption on NaPP ratio, with body weight and baseline body iron stores as covariates and subject as a random intercept.
Results
Of the women included, 46% were anemic and 26% were iron deficient. Iron bioavailability was 10.8, 9.8, and 11.0% for the 0:1, 3:1, and 6:1 NaPP:⁵⁷Fe treatments, respectively. There was no dose-response effect of an increasing NaPP:⁵⁷Fe ratio (β ± SE: 0.003 ± 0.028, P = 0.45).
Conclusions
In this study, the addition of NaPP did not increase iron bioavailability from FePP-fortified bouillon cubes. However, iron bioavailability from the Nigerian meals prepared with FePP-fortified bouillon cubes was higher than expected. These results are encouraging for the potential of bouillon cubes as a fortification vehicle. Further studies are needed to assess the effect of FePP-fortified bouillon cubes on improving iron status in low-income populations. This trial was registered at clinicaltrials.gov as NCT02815449.

I
Weirauch, C, Berenger J –M, Berniker L, Forero D, Forthman M, Frankenberg S, Freedman A, Gordon E, Hoey-Chamberlain R, Hwang WS, Marshall SA, Michael A, Paiero SM, Udah O, Watson C, Yeo M, Zhang G, Zhang J.  2014.  An illustrated identification key to assassin bug subfamilies and tribes (Hemiptera: Reduviidae). Canadian Journal of Arthropod Identification, Canada. No. 26(doi:10.3752/cjai.2014.26)
J
Ayoola, MD, Adebajo AC, Zotor FB, Pinkoane MG.  2019.  Justifying Antidiabetic Ethnomedicinal Claim of Senecio biafrae through Its Antihyperglycemic and Anti-Oxidant Activities. Ann Complement Altern Med. 2019; 1 (2). 1006 Abstract
n/a
L
ADEBIYI, RANTITAIBAT, Babalola O, Amuda-Yusuf G, RASHEED SHEHUABDULKADIR, ZUBAIR MUSAABIODUN.  2020.  Level of Awareness and Adherence to Health and Safety Regulations in Construction Industry in Kwara State of Nigeria. : Kaduna State University Environmental Sciences Journal Abstract
n/a
M
Schnittger, S, Bacher U, Zander AR, Klyuchnikov E, Haferlach T, Kröger N, Oyekunle A.  2011.  Molecular Diagnostics, Targeted Therapy, and the Indication for Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. Advances in Hematology. 2011 AbstractWebsite
n/a
N
Ojo, OO, Abubakar SA, Iwuozo EU, Nwazor EO, Ekenze OS, Farombi TH, Akinyemi RO, Williams UE, Bello AH, Wahab KW, Iyagba AM, Arigbodi O, Erameh CO, Komolafe MA, Fawale MB, Onwuegbuzie GA, Obiabo YO, Taiwo FT, Agu CE, Ekeh BC, Osaigbovo GO, Achoru CO, Arabambi B, Adeniji O, Nwani PO, Nwosu CM, Ademiluyi BA, Oyakhire SI, Nyandaiti Y, Rabiu M, Chapp-Jumbo EN, Balarabe SA, Otubogun FM, Obehighe EE, Kehinde AJ, Ani-Osheku I, Imarhiagbe FA, Dike FO, Adebowale AA, Agabi OP, Akpekpe JE, Ali MW, Odeniyi OA, Odiase FE, Abiodun OV, Olowoyo P, Osemwegie N, Oshinaike OO, Owolabi LF, Zubair YA, Rizig M, Okubadejo NU.  2020.  The Nigeria Parkinson Disease Registry: Process, Profile, and Prospects of a Collaborative Project, 2020. Movement Disorders. 35(8) Abstract

Background: Clinical disease registries are useful for quality improvement in care, benchmarking standards, and facilitating research. Collaborative networks established thence can enhance national and international studies by generating more robust samples and credible data and promote knowledge sharing and capacity building. This report describes the methodology, baseline data, and prospects of the Nigeria Parkinson Disease Registry. Methods: This national registry was established in November 2016. Ethics approval was obtained for all sites. Basic anonymized data for consecutive cases fulfilling the United Kingdom Parkinson's Disease Brain Bank criteria (except the exclusion criterion of affected family members) are registered by participating neurologists via a secure registry website (www.parkinsonnigeria.com) using a minimal common data capture format. Results: The registry had captured 578 participants from 5 of 6 geopolitical zones in Nigeria by July 2019 (72.5% men). Mean age at onset was 60.3 ± 10.7 years; median disease duration (interquartile range) was 36 months (18–60.5 months). Young-onset disease (<50 years) represented 15.2%. A family history was documented in 4.5% and 7.8% with age at onset <50 and ≥ 50, respectively. The most frequent initial symptom was tremor (45.3%). At inclusion, 93.4% were on treatment (54.5% on levodopa monotherapy). Per-capita direct cost for the registry was $3.37. Conclusions: This is the first published national Parkinson's disease registry in sub-Saharan Africa. The registry will serve as a platform for development of multipronged evidence-based policies and initiatives to improve quality of care of Parkinson's disease and research engagement in Nigeria. © 2020 International Parkinson and Movement Disorder Society.

Daramola, MO, Zampraka A, Aransiola EF, Adeogun GA.  2008.  Numerical modelling and simulation of liquid-impelled loop reactor.. Applied Sciences. 10 Abstract
n/a
O
Atere, CT, Gunina A, Zhu Z, Liu S, Kuzyakov Y, Chen L, Deng Y, Wu J, Ge T.  2020.  Organic matter stabilization in aggregates and density fractions in paddy soil depending on long-term fertilization: Tracing of pathways by 13C natural abundance. Biology and Biochemistry. 149:107931.
P
Chelban, V, Wilson MP, Warman Chardon J, Vandrovcova J, Zanetti MN, Zamba-Papanicolaou E, Efthymiou S, Pope S, Conte MR, Abis G et al..  2019.  PDXK mutations cause polyneuropathy responsive to pyridoxal 5'-phosphate supplementation, 2019. Annals of Neurology. 86(2) Abstract

Objective: To identify disease-causing variants in autosomal recessive axonal polyneuropathy with optic atrophy and provide targeted replacement therapy. Methods: We performed genome-wide sequencing, homozygosity mapping, and segregation analysis for novel disease-causing gene discovery. We used circular dichroism to show secondary structure changes and isothermal titration calorimetry to investigate the impact of variants on adenosine triphosphate (ATP) binding. Pathogenicity was further supported by enzymatic assays and mass spectroscopy on recombinant protein, patient-derived fibroblasts, plasma, and erythrocytes. Response to supplementation was measured with clinical validated rating scales, electrophysiology, and biochemical quantification. Results: We identified biallelic mutations in PDXK in 5 individuals from 2 unrelated families with primary axonal polyneuropathy and optic atrophy. The natural history of this disorder suggests that untreated, affected individuals become wheelchair-bound and blind. We identified conformational rearrangement in the mutant enzyme around the ATP-binding pocket. Low PDXK ATP binding resulted in decreased erythrocyte PDXK activity and low pyridoxal 5′-phosphate (PLP) concentrations. We rescued the clinical and biochemical profile with PLP supplementation in 1 family, improvement in power, pain, and fatigue contributing to patients regaining their ability to walk independently during the first year of PLP normalization. Interpretation: We show that mutations in PDXK cause autosomal recessive axonal peripheral polyneuropathy leading to disease via reduced PDXK enzymatic activity and low PLP. We show that the biochemical profile can be rescued with PLP supplementation associated with clinical improvement. As B6 is a cofactor in diverse essential biological pathways, our findings may have direct implications for neuropathies of unknown etiology characterized by reduced PLP levels. ANN NEUROL 2019;86:225–240.